Establishing a new human lung squamous cell carcinoma cell line, OMUL ‐1, expressing insulin‐like growth factor 1 receptor and programmed cell death ligand 1
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.15488 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Hiroaki Nagamine und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Squamous Cell, Receptor, IGF Type 1, B7-H1 Antigen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The Main Problem Squamous cell carcinoma is the second most prevalent type of non–small cell lung cancer. Analyzing the molecular mechanisms underlying lung carcinoma requires useful tools, such as squamous lung cancer cell lines.
Methods
A novel new lung squamous cell carcinoma cell line, OMUL‐1, was developed from the primary lung cancer of a 74‐year‐old man. We assessed the characteristics and behavior of OMUL‐1 cells were examined, including their growth kinetics, tumorigenicity in mice, histological properties, gene expression profiles using reverse transcription polymerase chain reaction (RT‐PCR), and RNA sequencing and invasion assays.
Results
OMUL‐1‐an adherent cell line‐resulted in 100% tumor formation when subcutaneously injected into mice. Histological analysis of the subcutaneous tumor using hematoxylin and eosin staining revealed squamous cell carcinoma with characteristics similar to those of the primary tumor (p40 and p63 were positive, and TTF‐1 was negative). An invasion assay demonstrated that OMUL‐1 had a lower invasion ability compared to that of other developed cell lines. RT‐PCR analysis and RNA sequencing indicated that OMUL‐1 cells expressed FGFR1 , FGFR2 , FGFR3 , FGFR4 , EGFR , HER2 , ErbB3 , ErbB4 , VEGFR3 , IGF1R , c‐MET , PDGFRa , and PDGFRb . Additionally, picropodophyllin (an IGF1R inhibitor) significantly inhibited the growth of OMUL‐1 cells. Immunohistochemistry revealed that IGF1R and PD‐L1 were expressed in both the primary and subcutaneous tumors.
Conclusions
We developed a novel new squamous cell lung carcinoma cell line, OMUL‐1, that expresses IGF1R and PD‐L1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
- Molecular Oncology and Therapeutics, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
- Department of Clinical Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
- Department of Thoracic Surgery, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
ORCID-Profile: Hiroaki Nagamine, Akira Sugimoto
Zitieren
APA
Nagamine, H., Yashiro, M., Mizutani, M., Sugimoto, A., Matsumoto, Y., Tani, Y., Kaneda, H., Yamada, K., Watanabe, T., Asai, K., Suzuki, S., & Kawaguchi, T. (2025). Establishing a new human lung squamous cell carcinoma cell line, OMUL ‐1, expressing insulin‐like growth factor 1 receptor and programmed cell death ligand 1. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15488
Vancouver
Nagamine H, Yashiro M, Mizutani M, Sugimoto A, Matsumoto Y, Tani Y, et al. Establishing a new human lung squamous cell carcinoma cell line, OMUL ‐1, expressing insulin‐like growth factor 1 receptor and programmed cell death ligand 1. Thoracic Cancer. 2025. doi:10.1111/1759-7714.15488
BibTeX
@article{Nagamine2025,
author = {Nagamine, Hiroaki and Yashiro, Masakazu and Mizutani, Megumi and Sugimoto, Akira and Matsumoto, Yoshiya and Tani, Yoko and Kaneda, Hiroyasu and Yamada, Kazuhiro and Watanabe, Tetsuya and Asai, Kazuhisa and Suzuki, Satoshi and Kawaguchi, Tomoya},
title = {Establishing a new human lung squamous cell carcinoma cell line, OMUL ‐1, expressing insulin‐like growth factor 1 receptor and programmed cell death ligand 1},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.15488}
}
EUVIMED